Tyrosine kinase inhibitor, preparation method and use thereof
A general formula compound and compound technology, applied in the field of chemical synthesis, can solve the problems of high toxicity and side effects, and achieve the effects of small toxicity and side effects, inhibition of tumor growth, and good targeting
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0026] Compound I preparation method:
[0027]
[0028] Compound I and its salts can be obtained by deprotecting Compound IX. Compound IX is an existing substance. During the implementation of this example, R 1 is trifluoromethane, m is 1, X 1 for N, R 4 stands for protected R 2 group, in this example R 2 The protecting group tert-butoxycarbonyl is reacted in a hydrochloric acid solution by heating in a water bath at 80°C, and the product is recovered after 30 minutes. The product is in the form of white powder, soluble in water, and has a pH of 6.4.
Embodiment 2
[0030] The dose dependence of the compound of the present invention was used to test the epiphyseal growth plate of rats.
[0031] Method: Alderley Park female young mice (4-8 weeks old, wostar-derived) were injected with the compound of the present invention (n=6) or excipients (n=5) at a dose of 0.25 mg / ml every day for 14 consecutive days. Epiphyseal joint tissue domains in experimental mice were stained with hematoxylin and eosin, and epiphyseal growth plate binding sites were measured using morphological impact analysis. The result is as figure 1 showed a dose-dependent increase in overgrown cartilage bands in the epiphyseal growth plate of growing mice. When the injection amount is 50 or 100 mg / ml / day, the ability of the compound of the present invention to inhibit VEGF signal is consistent with the anti-angiogenesis effect in vivo.
Embodiment 3
[0033] Experiment of the inhibitory effect of the compound of the present invention on human xenograft tumor in nude mice.
[0034] Method: 50 nude mice (male, 6 weeks old) were inoculated with PC-3 human prostate tumor until the tumor volume reached 0.2cm 2 At the same time, they were randomly divided into 5 groups, namely the control group, 100mg / kg / day dose group, 50mg / kg / day dose group, 25mg / kg / day dose group, and 12.5mg / kg / day dose group. Continuous administration for 7 days Day, intratumoral injection, observation for five weeks, the results are shown in Table 1.
[0035] Table 2 shows the inhibitory effect of oral administration of the compound of the present invention on human xenograft tumors in nude mice.
[0036] dosage
(mg / kg / kg /
sky)
Tumor volume (each observation day)
0
4
7
11
14
18
21
25
27
32
35
control
0.2
0.25
0.28
0.3 ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 